Stone House Investment Management’s Immunome IMNM Stock Holding History

Stone House Investment Management’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$106	Buy	+5	New	+$107	﹤0.01%	1285

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Stone House Investment Management's IMNM Position: Q2 2026 in Review

Stone House Investment Management opened a new position in Immunome (IMNM) in Q2 2026: 5 shares worth $106. The stake represents ﹤0.01% of the portfolio and ranks #1285 among its holdings.

202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

Stone House Investment Management held 5 shares of Immunome worth $106 as of Q2 2026.
Immunome was a new Stone House Investment Management position in Q2 2026.
Immunome made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #1285 holding.
202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.